{"gene":"EML4","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2007,"finding":"A small inversion within chromosome 2p [inv(2)(p21p23)] generates a fusion gene comprising portions of EML4 and ALK in NSCLC cells. Expression of the EML4-ALK fusion tyrosine kinase in mouse 3T3 fibroblasts produced transformed foci in culture and subcutaneous tumours in nude mice, demonstrating its oncogenic activity.","method":"Retroviral cDNA expression library functional screening (focus formation assay), RT-PCR, forced expression in NIH3T3 cells, nude mouse xenograft","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (focus formation, in vivo tumour assay, sequencing) in the discovery paper, subsequently replicated by many independent groups","pmids":["17625570"],"is_preprint":false},{"year":2008,"finding":"EML4-ALK oligomerizes constitutively in cells through the coiled-coil (dimerization) domain within the EML4 region, leading to constitutive activation of ALK kinase activity and oncogenicity both in vitro and in vivo.","method":"Biochemical analysis of fusion protein oligomerization, focus formation assay, in vivo tumour model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single review/synthesis paper describing the mechanism; original experiments referenced but abstract-level detail is limited","pmids":["19032370"],"is_preprint":false},{"year":2008,"finding":"EML4-ALK variants 3a and 3b (exon 6 of EML4 fused to exon 20 of ALK) exhibit marked transforming activity in vitro and oncogenic activity in vivo; a lung cancer cell line expressing endogenous variant 3 undergoes cell death upon treatment with a specific ALK catalytic activity inhibitor.","method":"RT-PCR identification of novel isoforms, focus formation assay, in vivo tumour assay, ALK inhibitor treatment of patient-derived cell line","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reconstitution of oncogenic activity in vitro and in vivo, pharmacological validation in patient-derived cell line","pmids":["18593892"],"is_preprint":false},{"year":2008,"finding":"EML4-ALK fusion drives lung adenocarcinoma formation in transgenic mice expressing the kinase specifically in lung alveolar epithelial cells; ALK kinase inhibitor treatment caused rapid disappearance of tumours, confirming essential kinase-dependent oncogenic role in vivo.","method":"Transgenic mouse model with lung-specific EML4-ALK expression, oral ALK inhibitor treatment, histopathology","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vivo genetic model with pharmacological validation, published in peer-reviewed journal","pmids":["19064915"],"is_preprint":false},{"year":2008,"finding":"Novel EML4-ALK isoforms containing exon 14 (variant 4) or exon 2 (variant 5) of EML4 fused to ALK exon 20 were identified; both variants manifest marked oncogenic activity and produce a cytoplasmic staining pattern with fine granular foci.","method":"Multiplex RT-PCR, genomic PCR, FISH, focus formation assay, immunohistochemistry","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal detection methods and functional oncogenicity assay","pmids":["18927303"],"is_preprint":false},{"year":2012,"finding":"Different EML4-ALK fusion variants (v1, v2, v3a, v3b) exhibit differential sensitivity to ALK kinase inhibitors crizotinib and TAE684, correlating with differences in protein stability. Sensitivity to HSP90 inhibition also varies by fusion variant. Combining ALK and HSP90 inhibitors produces synergistic cytotoxicity.","method":"Ba/F3 cell line model, cytotoxicity assays, protein stability measurements, HSP90 inhibitor treatment, intracellular localization studies","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (cell viability, protein stability, localization) across multiple constructs; independently confirmed by other labs","pmids":["22912387"],"is_preprint":false},{"year":2012,"finding":"In EML4-ALK-positive H2228 NSCLC cells, the ALK inhibitor TAE684 inhibits STAT3 but not ERK phosphorylation, yielding little effect on apoptosis alone; combining TAE684 with a MEK inhibitor induces marked apoptosis through simultaneous inhibition of STAT3-survivin and ERK-BIM pathways.","method":"Cell proliferation assay, Western blot for pSTAT3/pERK/survivin/BIM, apoptosis assay in NSCLC cell lines","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (signaling and cell death) in a single lab; mechanistic pathway placement established","pmids":["22240786"],"is_preprint":false},{"year":2015,"finding":"EML4-ALK activates RAS-MAPK signaling by engaging all three major RAS isoforms (HRAS, KRAS, NRAS) through the HELP domain of EML4. RAS-MAPK reactivation (via KRAS copy gain or reduced DUSP6) drives ALK inhibitor resistance in vitro and in patients.","method":"Genetic epistasis experiments, HELP domain deletion constructs, RAS isoform pull-down, patient biopsy analysis, MEK inhibitor combination studies in cell lines and mouse models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — domain-mapping, pull-down, multiple cell/animal models, corroborated with patient data","pmids":["26301689"],"is_preprint":false},{"year":2015,"finding":"EML4-ALK upregulates PD-L1 expression in NSCLC cells via activation of the MEK-ERK and PI3K-AKT signaling pathways. Forced EML4-ALK expression in Ba/F3 cells markedly increases PD-L1; ALK inhibition or ALK siRNA attenuates PD-L1 expression.","method":"Flow cytometry, RT-PCR, forced EML4-ALK expression in Ba/F3, RNAi knockdown, pathway inhibitor treatment (MEK-ERK, PI3K-AKT), immunohistochemistry","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (overexpression, knockdown, pharmacological inhibition) across multiple experimental systems","pmids":["26019170"],"is_preprint":false},{"year":2015,"finding":"EML4 proteins require an N-terminal trimerization domain (TD) for self-association. Crystal structures of the coiled-coil/TD from EML2 and EML4 reveal a trimeric oligomerization state driven by conserved hydrophobic residues and salt bridges, providing the structural basis for EML4-ALK constitutive activation. The TD is necessary and sufficient for self-association and is also essential for microtubule binding (requiring an adjacent basic region). EML4-ALK variant 3, which includes the TD and basic region but lacks WD40 repeats, localises to microtubules in recombinant systems and in patient-derived H2228 NSCLC cells.","method":"X-ray crystallography (crystal structures of EML2 and EML4 coiled-coils), domain deletion mutagenesis, self-association assay, microtubule binding assay, immunofluorescence in NSCLC cell line","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis and functional validation across multiple assays in one study","pmids":["25740311"],"is_preprint":false},{"year":2015,"finding":"EML4-ALK enhances PD-L1 expression through HIF-1α and STAT3 under both normoxia and hypoxia. EML4-ALK increases HIF-1α expression by increasing its transcription and decreasing its ubiquitination.","method":"Transfection of EML4-ALK into H23 cells, ALK knockdown/crizotinib in H2228 cells, HIF-1α transcription/ubiquitination assays, STAT3 inhibitor treatment, immunofluorescence, immunohistochemistry in patient tissues","journal":"Oncoimmunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (overexpression, knockdown, pharmacological, ubiquitination assay) in single lab","pmids":["27141364"],"is_preprint":false},{"year":2017,"finding":"SMYD2 lysine methyltransferase methylates ALK at lysine residues K1451, K1455, and K1610. SMYD2 knockdown or inhibition reduces phosphorylation of EML4-ALK protein. Substitution of K1610 with alanine reduces AKT phosphorylation and suppresses growth of EML4-ALK-positive NSCLC cells.","method":"In vitro methyltransferase assay, SMYD2 knockdown, site-directed mutagenesis (K→A), Western blot for pALK and pAKT, cell growth assay","journal":"Cancer science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methyltransferase assay plus mutagenesis plus cell-based functional readout in single lab; two orthogonal methods","pmids":["28370702"],"is_preprint":false},{"year":2019,"finding":"EML4 is a microtubule-associated protein whose N-terminal basic domain mediates binding to the acidic C-terminal tails of α- and β-tubulin on the microtubule surface (revealed by microtubule sedimentation and cryo-EM). In mitosis, NEK6 and NEK7 phosphorylate the EML4 N-terminal domain at Ser144 and Ser146, reducing microtubule affinity; depletion of NEK6/7 increases mitotic EML4-microtubule binding, and an S144A-S146A double mutant causes microtubule hyperstabilisation and chromosome congression defects.","method":"Cryo-electron microscopy with 3D reconstruction, microtubule sedimentation assay, in vitro kinase assay (NEK6/NEK7), site-directed mutagenesis, RNAi depletion, live-cell imaging of chromosome congression","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure, in vitro kinase assay, mutagenesis, and cell-based phenotype combined in single rigorous study","pmids":["31409757"],"is_preprint":false},{"year":2020,"finding":"EML4-ALK variant 3 (V3), which includes the N-terminal EML4 microtubule-binding region, recruits the NEK9 and NEK7 kinases to microtubules, causes microtubule stabilisation, formation of extended cytoplasmic protrusions, and increased cell migration. Constitutive activation of NEK9 perturbs cell morphology and accelerates migration in a microtubule-dependent, NEK7-dependent manner that does not require ALK activity.","method":"Cell line models expressing EML4-ALK V3, immunofluorescence, migration assays, NEK9/NEK7 overexpression/activation, microtubule depolymerisation rescue experiments","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (kinase recruitment, migration, cytoskeletal assays, genetic rescue) corroborated with patient survival data","pmids":["32184261"],"is_preprint":false},{"year":2021,"finding":"EML4-ALK variant 1 forms cytoplasmic condensates via liquid-liquid phase separation. Mutation of multiple aromatic residues in the EML4 region impairs phase separation, dampens downstream STAT3 phosphorylation, and significantly decreases malignant transformation and tumour formation in GEMMs.","method":"Phase separation imaging in cancer cell lines and GEMMs, organoid models, aromatic-residue mutagenesis, STAT3 phosphorylation assay, focus formation and in vivo tumour assay","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, multiple cell and in vivo models, orthogonal functional readouts in single study","pmids":["33976114"],"is_preprint":false},{"year":2021,"finding":"EML4-ALK V1 and V3 proteins form cytoplasmic foci containing components of MAPK, PLCγ and PI3K signalling pathways. ALK inhibitors ceritinib and lorlatinib dissolve these foci; V3 but not V1 protein re-localises to microtubules upon inhibitor treatment, recapitulated by a catalytically inactive EML4-ALK mutant. Alectinib increases foci formation of both wild-type and catalytically inactive V3 but not a Lys-Glu salt-bridge mutant. Foci formation requires an active ALK kinase conformation.","method":"Live-cell imaging of EML4-ALK foci, inhibitor treatment, catalytically inactive mutant, salt-bridge mutagenesis, subcellular fractionation/microtubule co-localisation, immunofluorescence","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple mutant constructs, pharmacological perturbations, and imaging across V1 and V3 in single rigorous study","pmids":["34661367"],"is_preprint":false},{"year":2021,"finding":"EML4-ALK activates the JAK2-STAT signalling pathway; JAK2, STAT1, STAT3, STAT5, and STAT6 are constitutively phosphorylated in EML4-ALK-expressing cells. Co-immunoprecipitation and immunofluorescence show activated STAT6 and JAK2 co-localise with ALK. EML4-ALK knockdown reduces STAT6 phosphorylation and decreases cell proliferation/viability.","method":"Signalling pathway microarray, Western blot, co-immunoprecipitation, immunofluorescence, siRNA knockdown, cell viability assay","journal":"BMC pulmonary medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus orthogonal co-localisation and knockdown, single lab","pmids":["34090412"],"is_preprint":false},{"year":2022,"finding":"EML4-ALK G1202R mutation induces epithelial-mesenchymal transition (EMT) and ceritinib resistance by activating the STAT3/Slug signalling pathway, upregulating STAT3 and Slug expression; combination of ALK and STAT3 inhibitors restores ceritinib sensitivity.","method":"Stable expression of EML4-ALK G1202R in A549 cells, migration/invasion assays, Western blot for STAT3/pSTAT3/Slug/EMT markers, combination inhibitor treatment","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — forced expression, functional phenotype, and signalling readouts in single lab","pmids":["35085771"],"is_preprint":false},{"year":2024,"finding":"EML4-ALK assemblies (condensates) sequester RTK adapter proteins GRB2 and SOS1, suppressing transmembrane RTK signalling. ALK inhibition dissolves condensates, releases sequestered adapters, and thereby resensitises RTK signalling; this releases pulsatile ERK reactivation driven by paracrine ligands from dying cells, promoting drug tolerance. Combination therapies blocking paracrine signalling counteract this survival mechanism.","method":"Optogenetics to manipulate EML4-ALK condensates, live-cell imaging, GRB2/SOS1 co-localisation and sequestration assays, ERK activity reporters, paracrine ligand blockade experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — optogenetic reconstitution, live-cell imaging, adapter sequestration assay, and functional rescue in single rigorous study","pmids":["39488530"],"is_preprint":false},{"year":2024,"finding":"EML4-ALK phase separation activates JAK-STAT signalling, which promotes adeno-to-squamous lineage transition in lung tumours. Club cells are identified as the main cell-of-origin for squamous transition. JAK1/2 inhibitor combined with ALK inhibitor overcomes resistance associated with squamous transition.","method":"Transgenic mouse models (GEMMs), lung organoid recapitulation of lineage transition, scRNA-seq, immunostaining, JAK-STAT pathway inhibition, patient tissue analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal systems (GEMMs, organoids, scRNA-seq, human tissue) with functional pharmacological rescue","pmids":["38284990"],"is_preprint":false},{"year":2015,"finding":"EML4-ALK-positive NSCLC cells are sensitive to ALK inhibitors; EGFR ligands (EGF, TGF-α, HB-EGF) activate EGFR and trigger bypass resistance to crizotinib and TAE684 via ERK1/2 and AKT. HGF activates Met/Gab1 and triggers resistance to TAE684 but not crizotinib. Paracrine supply of these ligands by endothelial cells and fibroblasts recapitulates resistance in co-culture.","method":"Cell viability assay, Western blot for pEGFR/pMet/pERK/pAKT, co-culture with endothelial cells and fibroblasts, EGFR-TKI and Met-TKI rescue experiments, in vivo xenograft","journal":"Clinical cancer research (originally 2012 published)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway readouts and co-culture system, single lab; published 2012","pmids":["22553343"],"is_preprint":false},{"year":2015,"finding":"EML4-ALK induces EMT and cancer stem cell-like properties (elevated CD133, enhanced mammosphere formation) in H1299 NSCLC cells; ERK1/2 inhibition reverses the EMT phenotype, placing ERK downstream of EML4-ALK in this process.","method":"Stable EML4-ALK expression in H1299 cells, invasion/migration assay, stem cell marker (CD133) quantification, mammosphere assay, ERK inhibitor treatment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional phenotypic assays with pharmacological pathway validation, single lab","pmids":["25735977"],"is_preprint":false}],"current_model":"EML4-ALK is an oncogenic fusion kinase generated by chromosomal inversion inv(2)(p21p23); its N-terminal EML4 trimerization domain (structurally characterised by crystallography) drives constitutive ALK kinase activation through trimeric self-association, and the resulting fusion protein forms cytoplasmic phase-separated condensates that concentrate MAPK, PLCγ, and PI3K signalling components while sequestering RTK adapters (GRB2, SOS1) to suppress basal RTK signalling; variant-specific properties (protein stability, microtubule localisation via the EML4 basic region, and condensate physical state) determine differential downstream signalling (RAS-MAPK via the HELP domain, JAK-STAT, PI3K-AKT), sensitivity to ALK inhibitors, and engagement of NEK9/NEK7 kinases to promote microtubule stabilisation and cell migration, with EML4 microtubule association regulated by NEK6/NEK7-mediated phosphorylation of Ser144/Ser146 during mitosis."},"narrative":{"mechanistic_narrative":"EML4 is a microtubule-associated protein whose N-terminal trimerization domain and adjacent basic region drive self-association and binding to the acidic C-terminal tails of α/β-tubulin, an activity governed in mitosis by NEK6/NEK7-mediated phosphorylation of Ser144/Ser146 that lowers microtubule affinity and prevents hyperstabilization and chromosome congression defects [PMID:25740311, PMID:31409757]. Clinically, EML4 is best characterized through the oncogenic EML4-ALK fusion produced by inv(2)(p21p23), in which the EML4 N-terminal portion confers constitutive ALK kinase activation through trimeric self-association, transforming cells in vitro and driving lung adenocarcinoma in vivo in a kinase-dependent manner [PMID:17625570, PMID:19064915, PMID:25740311]. The EML4 moiety also promotes the fusion protein's assembly into cytoplasmic condensates via liquid-liquid phase separation dependent on aromatic residues in the EML4 region; these condensates concentrate MAPK, PLCγ and PI3K signalling components and sequester the RTK adapters GRB2 and SOS1, coupling ALK activity to downstream STAT3 phosphorylation, malignant transformation, and suppression of basal RTK signalling [PMID:33976114, PMID:34661367, PMID:39488530]. EML4-ALK engages RAS-MAPK signalling through the EML4 HELP domain, which binds all three RAS isoforms, and activates JAK-STAT and PI3K-AKT cascades that drive PD-L1 induction, lineage plasticity, and resistance phenotypes [PMID:26301689, PMID:34090412, PMID:38284990]. Fusion variants differ in protein stability, microtubule localization, and condensate behavior—variant 3 retains the EML4 microtubule-binding region and recruits NEK9/NEK7 to microtubules to promote microtubule stabilization and cell migration independently of ALK activity—accounting for variant-specific signalling and inhibitor sensitivity [PMID:22912387, PMID:32184261, PMID:34661367].","teleology":[{"year":2007,"claim":"Established that a recurrent chromosomal inversion fuses EML4 to ALK and that the product is a bona fide oncogene, defining a new actionable driver in NSCLC.","evidence":"Retroviral cDNA expression library focus-formation screen, RT-PCR, and nude-mouse xenograft of the fusion","pmids":["17625570"],"confidence":"High","gaps":["Did not define how the EML4 portion activates ALK","No structural basis for activation"]},{"year":2008,"claim":"Showed that the EML4 coiled-coil region mediates constitutive oligomerization of the fusion, providing the first mechanistic explanation for ligand-independent ALK activation.","evidence":"Biochemical oligomerization analysis with focus formation and in vivo tumour assays","pmids":["19032370"],"confidence":"Medium","gaps":["Stoichiometry of self-association not resolved","Synthesis/review-level detail rather than primary structural data"]},{"year":2008,"claim":"Identified multiple EML4-ALK fusion variants and demonstrated their transforming activity and pharmacological dependence on ALK catalytic activity, motivating ALK-targeted therapy.","evidence":"RT-PCR isoform discovery, focus formation, in vivo tumour assays, ALK inhibitor treatment of patient-derived cells, IHC","pmids":["18593892","18927303","19064915"],"confidence":"High","gaps":["Why variants differ functionally was not addressed","Cell-of-origin not defined"]},{"year":2012,"claim":"Linked fusion variant identity to differential protein stability and inhibitor/HSP90 sensitivity, and placed downstream survival signalling on parallel STAT3 and ERK arms.","evidence":"Ba/F3 variant constructs with cytotoxicity, protein-stability, and localization assays; combination ALK/MEK inhibitor signalling studies in NSCLC lines","pmids":["22912387","22240786"],"confidence":"High","gaps":["Structural basis of variant stability differences unresolved","Did not establish condensate involvement"]},{"year":2015,"claim":"Defined the EML4 trimerization domain structurally and showed it is necessary and sufficient for self-association and, with the basic region, for microtubule binding, unifying ALK activation with EML4's native cytoskeletal role.","evidence":"X-ray crystallography of EML2/EML4 coiled-coils, domain-deletion mutagenesis, microtubule binding and immunofluorescence in H2228 cells","pmids":["25740311"],"confidence":"High","gaps":["Did not resolve how microtubule binding contributes to oncogenic signalling","Phase separation not yet implicated"]},{"year":2015,"claim":"Mapped EML4-ALK engagement of RAS-MAPK to the EML4 HELP domain and connected RAS-MAPK reactivation to acquired ALK inhibitor resistance, and showed EML4-ALK drives PD-L1, EMT, and bypass resistance through MAPK/PI3K and paracrine ligands.","evidence":"HELP-domain deletion constructs, RAS pull-downs, MEK-combination studies in cells/mice and patients; PD-L1 flow cytometry; co-culture paracrine resistance assays; EMT and stem-cell marker assays","pmids":["26301689","26019170","27141364","22553343","25735977"],"confidence":"High","gaps":["Spatial organization of these signalling outputs not yet explained","Relative contribution of each downstream arm to tumour maintenance unclear"]},{"year":2017,"claim":"Revealed a post-translational regulatory input by which SMYD2-mediated methylation of ALK residues supports fusion phosphorylation and AKT-driven growth.","evidence":"In vitro methyltransferase assay, SMYD2 knockdown, K→A mutagenesis, pALK/pAKT Western blot and growth assays","pmids":["28370702"],"confidence":"High","gaps":["Methylation site falls in the ALK rather than EML4 moiety","Single-lab, in vitro plus cell-based only"]},{"year":2019,"claim":"Established native EML4 as a tubulin-tail-binding microtubule-associated protein regulated by mitotic NEK6/NEK7 phosphorylation at Ser144/Ser146, defining its physiological function in mitotic microtubule dynamics.","evidence":"Cryo-EM reconstruction, microtubule sedimentation, in vitro NEK6/NEK7 kinase assays, S144A/S146A mutagenesis, RNAi, live-cell chromosome congression imaging","pmids":["31409757"],"confidence":"High","gaps":["How this regulation is co-opted in the fusion context not directly tested","Other kinase inputs not excluded"]},{"year":2020,"claim":"Showed that variant 3 EML4-ALK recruits NEK9/NEK7 to microtubules to stabilize them and drive migration independently of ALK kinase activity, revealing an ALK-independent EML4-driven mechanism of aggressiveness.","evidence":"EML4-ALK V3 cell models, immunofluorescence, migration assays, NEK9/NEK7 activation and microtubule-depolymerization rescue","pmids":["32184261"],"confidence":"High","gaps":["Whether this pathway is targetable clinically untested here","Generalizability to other variants unclear"]},{"year":2021,"claim":"Demonstrated that EML4-ALK forms phase-separated cytoplasmic condensates that concentrate MAPK/PLCγ/PI3K components and require an active ALK conformation, with aromatic EML4 residues driving phase separation, STAT3 signalling, and tumourigenesis.","evidence":"Phase-separation imaging in cells/GEMMs/organoids, aromatic-residue and salt-bridge mutagenesis, inhibitor-induced foci dissolution, STAT3 and tumour assays","pmids":["33976114","34661367","34090412"],"confidence":"High","gaps":["Quantitative link between condensate material state and signalling output incompletely defined","Variant-specific condensate differences only partly mapped"]},{"year":2024,"claim":"Connected condensate biology to therapy resistance: condensates sequester GRB2/SOS1 to suppress basal RTK signalling, and ALK inhibition releases adapters and pulsatile paracrine ERK reactivation, while phase-separation-driven JAK-STAT signalling promotes adeno-to-squamous lineage transition.","evidence":"Optogenetic condensate manipulation, GRB2/SOS1 sequestration and ERK reporter assays, paracrine blockade; GEMMs, organoids, scRNA-seq and JAK-STAT inhibition for lineage transition","pmids":["39488530","38284990"],"confidence":"High","gaps":["Long-term clinical efficacy of paracrine/JAK-STAT combination strategies not established","Determinants of squamous-transition cell-of-origin specificity incompletely defined"]},{"year":null,"claim":"It remains unresolved how native full-length EML4 microtubule and NEK regulation mechanistically intersect with fusion condensate formation to determine variant-specific signalling and durable resistance.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking microtubule localization, condensate state, and downstream pathway selection","Physiological (non-fusion) EML4 functions beyond mitosis uncharacterized in this corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[9,12]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,16]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[9,12,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,14,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,16,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[12]}],"complexes":[],"partners":["ALK","NEK7","NEK6","NEK9","GRB2","SOS1","RAS","SMYD2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9HC35","full_name":"Echinoderm microtubule-associated protein-like 4","aliases":["Restrictedly overexpressed proliferation-associated protein","Ropp 120"],"length_aa":981,"mass_kda":108.9,"function":"Essential for the formation and stability of microtubules (MTs) (PubMed:16890222, PubMed:31409757). Required for the organization of the mitotic spindle and for the proper attachment of kinetochores to MTs (PubMed:25789526). Promotes the recruitment of NUDC to the mitotic spindle for mitotic progression (PubMed:25789526)","subcellular_location":"Cytoplasm, cytoskeleton; Cytoplasm; Cytoplasm, cytoskeleton, spindle; Cytoplasm, cytoskeleton, microtubule organizing center; Midbody","url":"https://www.uniprot.org/uniprotkb/Q9HC35/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EML4","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DYNLL1","stoichiometry":0.2},{"gene":"DYNLL2","stoichiometry":0.2},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"NEK9","stoichiometry":0.2},{"gene":"SH3GL1","stoichiometry":0.2},{"gene":"TUBA1B","stoichiometry":0.2},{"gene":"TUBB4B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/EML4","total_profiled":1310},"omim":[{"mim_id":"607442","title":"ECHINODERM MICROTUBULE-ASSOCIATED PROTEIN-LIKE 4; EML4","url":"https://www.omim.org/entry/607442"},{"mim_id":"211980","title":"LUNG CANCER","url":"https://www.omim.org/entry/211980"},{"mim_id":"105590","title":"ALK RECEPTOR TYROSINE KINASE; ALK","url":"https://www.omim.org/entry/105590"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Microtubules","reliability":"Supported"},{"location":"Primary cilium","reliability":"Supported"},{"location":"Annulus","reliability":"Supported"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Calyx","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EML4"},"hgnc":{"alias_symbol":["ROPP120","ELP120"],"prev_symbol":["C2orf2"]},"alphafold":{"accession":"Q9HC35","domains":[{"cath_id":"2.130.10.10","chopping":"593-867","consensus_level":"medium","plddt":96.606,"start":593,"end":867}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HC35","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HC35-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HC35-F1-predicted_aligned_error_v6.png","plddt_mean":76.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EML4","jax_strain_url":"https://www.jax.org/strain/search?query=EML4"},"sequence":{"accession":"Q9HC35","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HC35.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HC35/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HC35"}},"corpus_meta":[{"pmid":"17625570","id":"PMC_17625570","title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17625570","citation_count":4311,"is_preprint":false},{"pmid":"19667264","id":"PMC_19667264","title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.","date":"2009","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19667264","citation_count":1569,"is_preprint":false},{"pmid":"18594010","id":"PMC_18594010","title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18594010","citation_count":839,"is_preprint":false},{"pmid":"19170230","id":"PMC_19170230","title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.","date":"2009","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19170230","citation_count":593,"is_preprint":false},{"pmid":"20418096","id":"PMC_20418096","title":"The biology and treatment of EML4-ALK non-small cell lung cancer.","date":"2010","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/20418096","citation_count":436,"is_preprint":false},{"pmid":"19064915","id":"PMC_19064915","title":"A mouse model for EML4-ALK-positive lung cancer.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19064915","citation_count":421,"is_preprint":false},{"pmid":"18927303","id":"PMC_18927303","title":"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18927303","citation_count":418,"is_preprint":false},{"pmid":"26019170","id":"PMC_26019170","title":"Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26019170","citation_count":401,"is_preprint":false},{"pmid":"30902613","id":"PMC_30902613","title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.","date":"2019","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30902613","citation_count":377,"is_preprint":false},{"pmid":"18593892","id":"PMC_18593892","title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18593892","citation_count":370,"is_preprint":false},{"pmid":"29373100","id":"PMC_29373100","title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.","date":"2018","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29373100","citation_count":287,"is_preprint":false},{"pmid":"20183914","id":"PMC_20183914","title":"Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.","date":"2010","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20183914","citation_count":274,"is_preprint":false},{"pmid":"19147828","id":"PMC_19147828","title":"EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19147828","citation_count":260,"is_preprint":false},{"pmid":"19737969","id":"PMC_19737969","title":"Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19737969","citation_count":252,"is_preprint":false},{"pmid":"20624322","id":"PMC_20624322","title":"Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20624322","citation_count":249,"is_preprint":false},{"pmid":"26301689","id":"PMC_26301689","title":"RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26301689","citation_count":243,"is_preprint":false},{"pmid":"22912387","id":"PMC_22912387","title":"Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22912387","citation_count":231,"is_preprint":false},{"pmid":"18320074","id":"PMC_18320074","title":"EML4-ALK fusion lung cancer: a rare acquired event.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18320074","citation_count":200,"is_preprint":false},{"pmid":"19032370","id":"PMC_19032370","title":"Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19032370","citation_count":189,"is_preprint":false},{"pmid":"28039177","id":"PMC_28039177","title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.","date":"2017","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28039177","citation_count":186,"is_preprint":false},{"pmid":"22825000","id":"PMC_22825000","title":"EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.","date":"2012","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22825000","citation_count":169,"is_preprint":false},{"pmid":"26544515","id":"PMC_26544515","title":"Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26544515","citation_count":164,"is_preprint":false},{"pmid":"28872581","id":"PMC_28872581","title":"EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/28872581","citation_count":149,"is_preprint":false},{"pmid":"27141364","id":"PMC_27141364","title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27141364","citation_count":136,"is_preprint":false},{"pmid":"18242762","id":"PMC_18242762","title":"EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.","date":"2008","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/18242762","citation_count":135,"is_preprint":false},{"pmid":"29099503","id":"PMC_29099503","title":"Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.","date":"2017","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/29099503","citation_count":124,"is_preprint":false},{"pmid":"30236141","id":"PMC_30236141","title":"Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30236141","citation_count":124,"is_preprint":false},{"pmid":"27141355","id":"PMC_27141355","title":"Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27141355","citation_count":122,"is_preprint":false},{"pmid":"22553343","id":"PMC_22553343","title":"Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22553343","citation_count":106,"is_preprint":false},{"pmid":"23341890","id":"PMC_23341890","title":"Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23341890","citation_count":105,"is_preprint":false},{"pmid":"34175504","id":"PMC_34175504","title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.","date":"2021","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/34175504","citation_count":103,"is_preprint":false},{"pmid":"26755435","id":"PMC_26755435","title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/26755435","citation_count":86,"is_preprint":false},{"pmid":"22124476","id":"PMC_22124476","title":"EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.","date":"2012","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22124476","citation_count":84,"is_preprint":false},{"pmid":"25740311","id":"PMC_25740311","title":"Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25740311","citation_count":80,"is_preprint":false},{"pmid":"26712101","id":"PMC_26712101","title":"Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.","date":"2015","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26712101","citation_count":76,"is_preprint":false},{"pmid":"21356191","id":"PMC_21356191","title":"Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.","date":"2011","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21356191","citation_count":72,"is_preprint":false},{"pmid":"35928804","id":"PMC_35928804","title":"EML4-ALK fusion gene in non-small cell lung cancer.","date":"2022","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35928804","citation_count":69,"is_preprint":false},{"pmid":"33976114","id":"PMC_33976114","title":"Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis.","date":"2021","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33976114","citation_count":63,"is_preprint":false},{"pmid":"21245935","id":"PMC_21245935","title":"Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.","date":"2011","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21245935","citation_count":57,"is_preprint":false},{"pmid":"37149843","id":"PMC_37149843","title":"EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.","date":"2023","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37149843","citation_count":56,"is_preprint":false},{"pmid":"25806283","id":"PMC_25806283","title":"Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.","date":"2014","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25806283","citation_count":56,"is_preprint":false},{"pmid":"18414414","id":"PMC_18414414","title":"EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.","date":"2008","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18414414","citation_count":55,"is_preprint":false},{"pmid":"34661367","id":"PMC_34661367","title":"Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/34661367","citation_count":54,"is_preprint":false},{"pmid":"23919423","id":"PMC_23919423","title":"Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.","date":"2013","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/23919423","citation_count":52,"is_preprint":false},{"pmid":"25706305","id":"PMC_25706305","title":"Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25706305","citation_count":49,"is_preprint":false},{"pmid":"24722159","id":"PMC_24722159","title":"ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung.","date":"2014","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24722159","citation_count":49,"is_preprint":false},{"pmid":"24952482","id":"PMC_24952482","title":"Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24952482","citation_count":47,"is_preprint":false},{"pmid":"25375092","id":"PMC_25375092","title":"Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25375092","citation_count":47,"is_preprint":false},{"pmid":"37541389","id":"PMC_37541389","title":"Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.","date":"2023","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37541389","citation_count":45,"is_preprint":false},{"pmid":"22240786","id":"PMC_22240786","title":"Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.","date":"2012","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22240786","citation_count":45,"is_preprint":false},{"pmid":"25592111","id":"PMC_25592111","title":"Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.","date":"2015","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25592111","citation_count":44,"is_preprint":false},{"pmid":"29304828","id":"PMC_29304828","title":"Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.","date":"2018","source":"Radiation oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29304828","citation_count":43,"is_preprint":false},{"pmid":"25609979","id":"PMC_25609979","title":"Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung.","date":"2015","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25609979","citation_count":42,"is_preprint":false},{"pmid":"23408463","id":"PMC_23408463","title":"Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.","date":"2013","source":"Cancer cytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23408463","citation_count":41,"is_preprint":false},{"pmid":"24598368","id":"PMC_24598368","title":"Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.","date":"2014","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/24598368","citation_count":40,"is_preprint":false},{"pmid":"22964709","id":"PMC_22964709","title":"EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.","date":"2012","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22964709","citation_count":39,"is_preprint":false},{"pmid":"32184261","id":"PMC_32184261","title":"EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.","date":"2020","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/32184261","citation_count":38,"is_preprint":false},{"pmid":"31409757","id":"PMC_31409757","title":"Mitotic phosphorylation by NEK6 and NEK7 reduces the microtubule affinity of EML4 to promote chromosome congression.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31409757","citation_count":38,"is_preprint":false},{"pmid":"33017727","id":"PMC_33017727","title":"Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.","date":"2020","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/33017727","citation_count":36,"is_preprint":false},{"pmid":"28370702","id":"PMC_28370702","title":"Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.","date":"2017","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/28370702","citation_count":36,"is_preprint":false},{"pmid":"37036171","id":"PMC_37036171","title":"Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37036171","citation_count":35,"is_preprint":false},{"pmid":"25581823","id":"PMC_25581823","title":"In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.","date":"2015","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/25581823","citation_count":32,"is_preprint":false},{"pmid":"28938691","id":"PMC_28938691","title":"Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28938691","citation_count":31,"is_preprint":false},{"pmid":"22311682","id":"PMC_22311682","title":"The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.","date":"2012","source":"Current oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22311682","citation_count":30,"is_preprint":false},{"pmid":"25735977","id":"PMC_25735977","title":"EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25735977","citation_count":30,"is_preprint":false},{"pmid":"21475126","id":"PMC_21475126","title":"New targets in advanced NSCLC: EML4-ALK.","date":"2011","source":"Clinical advances in hematology & oncology : H&O","url":"https://pubmed.ncbi.nlm.nih.gov/21475126","citation_count":29,"is_preprint":false},{"pmid":"25360721","id":"PMC_25360721","title":"Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25360721","citation_count":29,"is_preprint":false},{"pmid":"33569295","id":"PMC_33569295","title":"A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.","date":"2021","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33569295","citation_count":28,"is_preprint":false},{"pmid":"29774063","id":"PMC_29774063","title":"Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/29774063","citation_count":27,"is_preprint":false},{"pmid":"26781614","id":"PMC_26781614","title":"ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.","date":"2016","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26781614","citation_count":27,"is_preprint":false},{"pmid":"33878728","id":"PMC_33878728","title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33878728","citation_count":26,"is_preprint":false},{"pmid":"27836576","id":"PMC_27836576","title":"Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.","date":"2016","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27836576","citation_count":26,"is_preprint":false},{"pmid":"35085771","id":"PMC_35085771","title":"EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35085771","citation_count":25,"is_preprint":false},{"pmid":"35117067","id":"PMC_35117067","title":"EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy.","date":"2019","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35117067","citation_count":24,"is_preprint":false},{"pmid":"31138506","id":"PMC_31138506","title":"Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.","date":"2019","source":"Clinical lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31138506","citation_count":24,"is_preprint":false},{"pmid":"24674157","id":"PMC_24674157","title":"Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.","date":"2014","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/24674157","citation_count":24,"is_preprint":false},{"pmid":"30791979","id":"PMC_30791979","title":"miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30791979","citation_count":23,"is_preprint":false},{"pmid":"24277751","id":"PMC_24277751","title":"Pulmonary inflammatory myofibroblastic tumor harboring EML4-ALK fusion gene.","date":"2013","source":"Japanese journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24277751","citation_count":23,"is_preprint":false},{"pmid":"34090412","id":"PMC_34090412","title":"EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.","date":"2021","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34090412","citation_count":22,"is_preprint":false},{"pmid":"33241586","id":"PMC_33241586","title":"Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular hyalinization showing EML4-ALK fusion.","date":"2020","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33241586","citation_count":22,"is_preprint":false},{"pmid":"22323876","id":"PMC_22323876","title":"EML4-ALK fusion gene in Korean non-small cell lung cancer.","date":"2012","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/22323876","citation_count":21,"is_preprint":false},{"pmid":"33255340","id":"PMC_33255340","title":"Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33255340","citation_count":21,"is_preprint":false},{"pmid":"36739466","id":"PMC_36739466","title":"Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.","date":"2023","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36739466","citation_count":20,"is_preprint":false},{"pmid":"25971657","id":"PMC_25971657","title":"The EML4-ALK oncogene: targeting an essential growth driver in human cancer.","date":"2015","source":"Proceedings of the Japan Academy. Series B, Physical and biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25971657","citation_count":19,"is_preprint":false},{"pmid":"35572973","id":"PMC_35572973","title":"EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35572973","citation_count":18,"is_preprint":false},{"pmid":"30281099","id":"PMC_30281099","title":"Genome-wide meta-analysis identifies BARX1 and EML4-MTA3 as new loci associated with infantile hypertrophic pyloric stenosis.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30281099","citation_count":18,"is_preprint":false},{"pmid":"35642002","id":"PMC_35642002","title":"Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35642002","citation_count":18,"is_preprint":false},{"pmid":"33170538","id":"PMC_33170538","title":"Spindle cell neoplasm with EML4-ALK gene fusion presenting as an intraosseous vertebral mass.","date":"2020","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33170538","citation_count":17,"is_preprint":false},{"pmid":"33776709","id":"PMC_33776709","title":"Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature.","date":"2021","source":"Case reports in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33776709","citation_count":17,"is_preprint":false},{"pmid":"38284990","id":"PMC_38284990","title":"EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38284990","citation_count":16,"is_preprint":false},{"pmid":"32047559","id":"PMC_32047559","title":"Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer.","date":"2020","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32047559","citation_count":16,"is_preprint":false},{"pmid":"24754584","id":"PMC_24754584","title":"Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients.","date":"2014","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24754584","citation_count":15,"is_preprint":false},{"pmid":"39488530","id":"PMC_39488530","title":"Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39488530","citation_count":14,"is_preprint":false},{"pmid":"32558295","id":"PMC_32558295","title":"Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32558295","citation_count":14,"is_preprint":false},{"pmid":"33907223","id":"PMC_33907223","title":"ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33907223","citation_count":14,"is_preprint":false},{"pmid":"37907052","id":"PMC_37907052","title":"Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.","date":"2023","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/37907052","citation_count":14,"is_preprint":false},{"pmid":"25407901","id":"PMC_25407901","title":"Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25407901","citation_count":14,"is_preprint":false},{"pmid":"35280868","id":"PMC_35280868","title":"Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35280868","citation_count":14,"is_preprint":false},{"pmid":"29251824","id":"PMC_29251824","title":"Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.","date":"2017","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29251824","citation_count":14,"is_preprint":false},{"pmid":"37302317","id":"PMC_37302317","title":"Discovery of potent and effective inhibitors containing sulfoxide structures targeting EML4-ALK rearrangement and EGFR mutant non-small cell lung cancer.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37302317","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54011,"output_tokens":5814,"usd":0.124621,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14390,"output_tokens":4034,"usd":0.0864,"stage2_stop_reason":"end_turn"},"total_usd":0.211021,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"A small inversion within chromosome 2p [inv(2)(p21p23)] generates a fusion gene comprising portions of EML4 and ALK in NSCLC cells. Expression of the EML4-ALK fusion tyrosine kinase in mouse 3T3 fibroblasts produced transformed foci in culture and subcutaneous tumours in nude mice, demonstrating its oncogenic activity.\",\n      \"method\": \"Retroviral cDNA expression library functional screening (focus formation assay), RT-PCR, forced expression in NIH3T3 cells, nude mouse xenograft\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (focus formation, in vivo tumour assay, sequencing) in the discovery paper, subsequently replicated by many independent groups\",\n      \"pmids\": [\"17625570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EML4-ALK oligomerizes constitutively in cells through the coiled-coil (dimerization) domain within the EML4 region, leading to constitutive activation of ALK kinase activity and oncogenicity both in vitro and in vivo.\",\n      \"method\": \"Biochemical analysis of fusion protein oligomerization, focus formation assay, in vivo tumour model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single review/synthesis paper describing the mechanism; original experiments referenced but abstract-level detail is limited\",\n      \"pmids\": [\"19032370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EML4-ALK variants 3a and 3b (exon 6 of EML4 fused to exon 20 of ALK) exhibit marked transforming activity in vitro and oncogenic activity in vivo; a lung cancer cell line expressing endogenous variant 3 undergoes cell death upon treatment with a specific ALK catalytic activity inhibitor.\",\n      \"method\": \"RT-PCR identification of novel isoforms, focus formation assay, in vivo tumour assay, ALK inhibitor treatment of patient-derived cell line\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reconstitution of oncogenic activity in vitro and in vivo, pharmacological validation in patient-derived cell line\",\n      \"pmids\": [\"18593892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EML4-ALK fusion drives lung adenocarcinoma formation in transgenic mice expressing the kinase specifically in lung alveolar epithelial cells; ALK kinase inhibitor treatment caused rapid disappearance of tumours, confirming essential kinase-dependent oncogenic role in vivo.\",\n      \"method\": \"Transgenic mouse model with lung-specific EML4-ALK expression, oral ALK inhibitor treatment, histopathology\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vivo genetic model with pharmacological validation, published in peer-reviewed journal\",\n      \"pmids\": [\"19064915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Novel EML4-ALK isoforms containing exon 14 (variant 4) or exon 2 (variant 5) of EML4 fused to ALK exon 20 were identified; both variants manifest marked oncogenic activity and produce a cytoplasmic staining pattern with fine granular foci.\",\n      \"method\": \"Multiplex RT-PCR, genomic PCR, FISH, focus formation assay, immunohistochemistry\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal detection methods and functional oncogenicity assay\",\n      \"pmids\": [\"18927303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Different EML4-ALK fusion variants (v1, v2, v3a, v3b) exhibit differential sensitivity to ALK kinase inhibitors crizotinib and TAE684, correlating with differences in protein stability. Sensitivity to HSP90 inhibition also varies by fusion variant. Combining ALK and HSP90 inhibitors produces synergistic cytotoxicity.\",\n      \"method\": \"Ba/F3 cell line model, cytotoxicity assays, protein stability measurements, HSP90 inhibitor treatment, intracellular localization studies\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (cell viability, protein stability, localization) across multiple constructs; independently confirmed by other labs\",\n      \"pmids\": [\"22912387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In EML4-ALK-positive H2228 NSCLC cells, the ALK inhibitor TAE684 inhibits STAT3 but not ERK phosphorylation, yielding little effect on apoptosis alone; combining TAE684 with a MEK inhibitor induces marked apoptosis through simultaneous inhibition of STAT3-survivin and ERK-BIM pathways.\",\n      \"method\": \"Cell proliferation assay, Western blot for pSTAT3/pERK/survivin/BIM, apoptosis assay in NSCLC cell lines\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (signaling and cell death) in a single lab; mechanistic pathway placement established\",\n      \"pmids\": [\"22240786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4-ALK activates RAS-MAPK signaling by engaging all three major RAS isoforms (HRAS, KRAS, NRAS) through the HELP domain of EML4. RAS-MAPK reactivation (via KRAS copy gain or reduced DUSP6) drives ALK inhibitor resistance in vitro and in patients.\",\n      \"method\": \"Genetic epistasis experiments, HELP domain deletion constructs, RAS isoform pull-down, patient biopsy analysis, MEK inhibitor combination studies in cell lines and mouse models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — domain-mapping, pull-down, multiple cell/animal models, corroborated with patient data\",\n      \"pmids\": [\"26301689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4-ALK upregulates PD-L1 expression in NSCLC cells via activation of the MEK-ERK and PI3K-AKT signaling pathways. Forced EML4-ALK expression in Ba/F3 cells markedly increases PD-L1; ALK inhibition or ALK siRNA attenuates PD-L1 expression.\",\n      \"method\": \"Flow cytometry, RT-PCR, forced EML4-ALK expression in Ba/F3, RNAi knockdown, pathway inhibitor treatment (MEK-ERK, PI3K-AKT), immunohistochemistry\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (overexpression, knockdown, pharmacological inhibition) across multiple experimental systems\",\n      \"pmids\": [\"26019170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4 proteins require an N-terminal trimerization domain (TD) for self-association. Crystal structures of the coiled-coil/TD from EML2 and EML4 reveal a trimeric oligomerization state driven by conserved hydrophobic residues and salt bridges, providing the structural basis for EML4-ALK constitutive activation. The TD is necessary and sufficient for self-association and is also essential for microtubule binding (requiring an adjacent basic region). EML4-ALK variant 3, which includes the TD and basic region but lacks WD40 repeats, localises to microtubules in recombinant systems and in patient-derived H2228 NSCLC cells.\",\n      \"method\": \"X-ray crystallography (crystal structures of EML2 and EML4 coiled-coils), domain deletion mutagenesis, self-association assay, microtubule binding assay, immunofluorescence in NSCLC cell line\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis and functional validation across multiple assays in one study\",\n      \"pmids\": [\"25740311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4-ALK enhances PD-L1 expression through HIF-1α and STAT3 under both normoxia and hypoxia. EML4-ALK increases HIF-1α expression by increasing its transcription and decreasing its ubiquitination.\",\n      \"method\": \"Transfection of EML4-ALK into H23 cells, ALK knockdown/crizotinib in H2228 cells, HIF-1α transcription/ubiquitination assays, STAT3 inhibitor treatment, immunofluorescence, immunohistochemistry in patient tissues\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (overexpression, knockdown, pharmacological, ubiquitination assay) in single lab\",\n      \"pmids\": [\"27141364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMYD2 lysine methyltransferase methylates ALK at lysine residues K1451, K1455, and K1610. SMYD2 knockdown or inhibition reduces phosphorylation of EML4-ALK protein. Substitution of K1610 with alanine reduces AKT phosphorylation and suppresses growth of EML4-ALK-positive NSCLC cells.\",\n      \"method\": \"In vitro methyltransferase assay, SMYD2 knockdown, site-directed mutagenesis (K→A), Western blot for pALK and pAKT, cell growth assay\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methyltransferase assay plus mutagenesis plus cell-based functional readout in single lab; two orthogonal methods\",\n      \"pmids\": [\"28370702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EML4 is a microtubule-associated protein whose N-terminal basic domain mediates binding to the acidic C-terminal tails of α- and β-tubulin on the microtubule surface (revealed by microtubule sedimentation and cryo-EM). In mitosis, NEK6 and NEK7 phosphorylate the EML4 N-terminal domain at Ser144 and Ser146, reducing microtubule affinity; depletion of NEK6/7 increases mitotic EML4-microtubule binding, and an S144A-S146A double mutant causes microtubule hyperstabilisation and chromosome congression defects.\",\n      \"method\": \"Cryo-electron microscopy with 3D reconstruction, microtubule sedimentation assay, in vitro kinase assay (NEK6/NEK7), site-directed mutagenesis, RNAi depletion, live-cell imaging of chromosome congression\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure, in vitro kinase assay, mutagenesis, and cell-based phenotype combined in single rigorous study\",\n      \"pmids\": [\"31409757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EML4-ALK variant 3 (V3), which includes the N-terminal EML4 microtubule-binding region, recruits the NEK9 and NEK7 kinases to microtubules, causes microtubule stabilisation, formation of extended cytoplasmic protrusions, and increased cell migration. Constitutive activation of NEK9 perturbs cell morphology and accelerates migration in a microtubule-dependent, NEK7-dependent manner that does not require ALK activity.\",\n      \"method\": \"Cell line models expressing EML4-ALK V3, immunofluorescence, migration assays, NEK9/NEK7 overexpression/activation, microtubule depolymerisation rescue experiments\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (kinase recruitment, migration, cytoskeletal assays, genetic rescue) corroborated with patient survival data\",\n      \"pmids\": [\"32184261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EML4-ALK variant 1 forms cytoplasmic condensates via liquid-liquid phase separation. Mutation of multiple aromatic residues in the EML4 region impairs phase separation, dampens downstream STAT3 phosphorylation, and significantly decreases malignant transformation and tumour formation in GEMMs.\",\n      \"method\": \"Phase separation imaging in cancer cell lines and GEMMs, organoid models, aromatic-residue mutagenesis, STAT3 phosphorylation assay, focus formation and in vivo tumour assay\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, multiple cell and in vivo models, orthogonal functional readouts in single study\",\n      \"pmids\": [\"33976114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EML4-ALK V1 and V3 proteins form cytoplasmic foci containing components of MAPK, PLCγ and PI3K signalling pathways. ALK inhibitors ceritinib and lorlatinib dissolve these foci; V3 but not V1 protein re-localises to microtubules upon inhibitor treatment, recapitulated by a catalytically inactive EML4-ALK mutant. Alectinib increases foci formation of both wild-type and catalytically inactive V3 but not a Lys-Glu salt-bridge mutant. Foci formation requires an active ALK kinase conformation.\",\n      \"method\": \"Live-cell imaging of EML4-ALK foci, inhibitor treatment, catalytically inactive mutant, salt-bridge mutagenesis, subcellular fractionation/microtubule co-localisation, immunofluorescence\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple mutant constructs, pharmacological perturbations, and imaging across V1 and V3 in single rigorous study\",\n      \"pmids\": [\"34661367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EML4-ALK activates the JAK2-STAT signalling pathway; JAK2, STAT1, STAT3, STAT5, and STAT6 are constitutively phosphorylated in EML4-ALK-expressing cells. Co-immunoprecipitation and immunofluorescence show activated STAT6 and JAK2 co-localise with ALK. EML4-ALK knockdown reduces STAT6 phosphorylation and decreases cell proliferation/viability.\",\n      \"method\": \"Signalling pathway microarray, Western blot, co-immunoprecipitation, immunofluorescence, siRNA knockdown, cell viability assay\",\n      \"journal\": \"BMC pulmonary medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus orthogonal co-localisation and knockdown, single lab\",\n      \"pmids\": [\"34090412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EML4-ALK G1202R mutation induces epithelial-mesenchymal transition (EMT) and ceritinib resistance by activating the STAT3/Slug signalling pathway, upregulating STAT3 and Slug expression; combination of ALK and STAT3 inhibitors restores ceritinib sensitivity.\",\n      \"method\": \"Stable expression of EML4-ALK G1202R in A549 cells, migration/invasion assays, Western blot for STAT3/pSTAT3/Slug/EMT markers, combination inhibitor treatment\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — forced expression, functional phenotype, and signalling readouts in single lab\",\n      \"pmids\": [\"35085771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EML4-ALK assemblies (condensates) sequester RTK adapter proteins GRB2 and SOS1, suppressing transmembrane RTK signalling. ALK inhibition dissolves condensates, releases sequestered adapters, and thereby resensitises RTK signalling; this releases pulsatile ERK reactivation driven by paracrine ligands from dying cells, promoting drug tolerance. Combination therapies blocking paracrine signalling counteract this survival mechanism.\",\n      \"method\": \"Optogenetics to manipulate EML4-ALK condensates, live-cell imaging, GRB2/SOS1 co-localisation and sequestration assays, ERK activity reporters, paracrine ligand blockade experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — optogenetic reconstitution, live-cell imaging, adapter sequestration assay, and functional rescue in single rigorous study\",\n      \"pmids\": [\"39488530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EML4-ALK phase separation activates JAK-STAT signalling, which promotes adeno-to-squamous lineage transition in lung tumours. Club cells are identified as the main cell-of-origin for squamous transition. JAK1/2 inhibitor combined with ALK inhibitor overcomes resistance associated with squamous transition.\",\n      \"method\": \"Transgenic mouse models (GEMMs), lung organoid recapitulation of lineage transition, scRNA-seq, immunostaining, JAK-STAT pathway inhibition, patient tissue analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal systems (GEMMs, organoids, scRNA-seq, human tissue) with functional pharmacological rescue\",\n      \"pmids\": [\"38284990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4-ALK-positive NSCLC cells are sensitive to ALK inhibitors; EGFR ligands (EGF, TGF-α, HB-EGF) activate EGFR and trigger bypass resistance to crizotinib and TAE684 via ERK1/2 and AKT. HGF activates Met/Gab1 and triggers resistance to TAE684 but not crizotinib. Paracrine supply of these ligands by endothelial cells and fibroblasts recapitulates resistance in co-culture.\",\n      \"method\": \"Cell viability assay, Western blot for pEGFR/pMet/pERK/pAKT, co-culture with endothelial cells and fibroblasts, EGFR-TKI and Met-TKI rescue experiments, in vivo xenograft\",\n      \"journal\": \"Clinical cancer research (originally 2012 published)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway readouts and co-culture system, single lab; published 2012\",\n      \"pmids\": [\"22553343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EML4-ALK induces EMT and cancer stem cell-like properties (elevated CD133, enhanced mammosphere formation) in H1299 NSCLC cells; ERK1/2 inhibition reverses the EMT phenotype, placing ERK downstream of EML4-ALK in this process.\",\n      \"method\": \"Stable EML4-ALK expression in H1299 cells, invasion/migration assay, stem cell marker (CD133) quantification, mammosphere assay, ERK inhibitor treatment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional phenotypic assays with pharmacological pathway validation, single lab\",\n      \"pmids\": [\"25735977\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EML4-ALK is an oncogenic fusion kinase generated by chromosomal inversion inv(2)(p21p23); its N-terminal EML4 trimerization domain (structurally characterised by crystallography) drives constitutive ALK kinase activation through trimeric self-association, and the resulting fusion protein forms cytoplasmic phase-separated condensates that concentrate MAPK, PLCγ, and PI3K signalling components while sequestering RTK adapters (GRB2, SOS1) to suppress basal RTK signalling; variant-specific properties (protein stability, microtubule localisation via the EML4 basic region, and condensate physical state) determine differential downstream signalling (RAS-MAPK via the HELP domain, JAK-STAT, PI3K-AKT), sensitivity to ALK inhibitors, and engagement of NEK9/NEK7 kinases to promote microtubule stabilisation and cell migration, with EML4 microtubule association regulated by NEK6/NEK7-mediated phosphorylation of Ser144/Ser146 during mitosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EML4 is a microtubule-associated protein whose N-terminal trimerization domain and adjacent basic region drive self-association and binding to the acidic C-terminal tails of α/β-tubulin, an activity governed in mitosis by NEK6/NEK7-mediated phosphorylation of Ser144/Ser146 that lowers microtubule affinity and prevents hyperstabilization and chromosome congression defects [#9, #12]. Clinically, EML4 is best characterized through the oncogenic EML4-ALK fusion produced by inv(2)(p21p23), in which the EML4 N-terminal portion confers constitutive ALK kinase activation through trimeric self-association, transforming cells in vitro and driving lung adenocarcinoma in vivo in a kinase-dependent manner [#0, #3, #9]. The EML4 moiety also promotes the fusion protein's assembly into cytoplasmic condensates via liquid-liquid phase separation dependent on aromatic residues in the EML4 region; these condensates concentrate MAPK, PLCγ and PI3K signalling components and sequester the RTK adapters GRB2 and SOS1, coupling ALK activity to downstream STAT3 phosphorylation, malignant transformation, and suppression of basal RTK signalling [#14, #15, #18]. EML4-ALK engages RAS-MAPK signalling through the EML4 HELP domain, which binds all three RAS isoforms, and activates JAK-STAT and PI3K-AKT cascades that drive PD-L1 induction, lineage plasticity, and resistance phenotypes [#7, #16, #19]. Fusion variants differ in protein stability, microtubule localization, and condensate behavior—variant 3 retains the EML4 microtubule-binding region and recruits NEK9/NEK7 to microtubules to promote microtubule stabilization and cell migration independently of ALK activity—accounting for variant-specific signalling and inhibitor sensitivity [#5, #13, #15].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established that a recurrent chromosomal inversion fuses EML4 to ALK and that the product is a bona fide oncogene, defining a new actionable driver in NSCLC.\",\n      \"evidence\": \"Retroviral cDNA expression library focus-formation screen, RT-PCR, and nude-mouse xenograft of the fusion\",\n      \"pmids\": [\"17625570\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how the EML4 portion activates ALK\", \"No structural basis for activation\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed that the EML4 coiled-coil region mediates constitutive oligomerization of the fusion, providing the first mechanistic explanation for ligand-independent ALK activation.\",\n      \"evidence\": \"Biochemical oligomerization analysis with focus formation and in vivo tumour assays\",\n      \"pmids\": [\"19032370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry of self-association not resolved\", \"Synthesis/review-level detail rather than primary structural data\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified multiple EML4-ALK fusion variants and demonstrated their transforming activity and pharmacological dependence on ALK catalytic activity, motivating ALK-targeted therapy.\",\n      \"evidence\": \"RT-PCR isoform discovery, focus formation, in vivo tumour assays, ALK inhibitor treatment of patient-derived cells, IHC\",\n      \"pmids\": [\"18593892\", \"18927303\", \"19064915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why variants differ functionally was not addressed\", \"Cell-of-origin not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked fusion variant identity to differential protein stability and inhibitor/HSP90 sensitivity, and placed downstream survival signalling on parallel STAT3 and ERK arms.\",\n      \"evidence\": \"Ba/F3 variant constructs with cytotoxicity, protein-stability, and localization assays; combination ALK/MEK inhibitor signalling studies in NSCLC lines\",\n      \"pmids\": [\"22912387\", \"22240786\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of variant stability differences unresolved\", \"Did not establish condensate involvement\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the EML4 trimerization domain structurally and showed it is necessary and sufficient for self-association and, with the basic region, for microtubule binding, unifying ALK activation with EML4's native cytoskeletal role.\",\n      \"evidence\": \"X-ray crystallography of EML2/EML4 coiled-coils, domain-deletion mutagenesis, microtubule binding and immunofluorescence in H2228 cells\",\n      \"pmids\": [\"25740311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how microtubule binding contributes to oncogenic signalling\", \"Phase separation not yet implicated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped EML4-ALK engagement of RAS-MAPK to the EML4 HELP domain and connected RAS-MAPK reactivation to acquired ALK inhibitor resistance, and showed EML4-ALK drives PD-L1, EMT, and bypass resistance through MAPK/PI3K and paracrine ligands.\",\n      \"evidence\": \"HELP-domain deletion constructs, RAS pull-downs, MEK-combination studies in cells/mice and patients; PD-L1 flow cytometry; co-culture paracrine resistance assays; EMT and stem-cell marker assays\",\n      \"pmids\": [\"26301689\", \"26019170\", \"27141364\", \"22553343\", \"25735977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial organization of these signalling outputs not yet explained\", \"Relative contribution of each downstream arm to tumour maintenance unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a post-translational regulatory input by which SMYD2-mediated methylation of ALK residues supports fusion phosphorylation and AKT-driven growth.\",\n      \"evidence\": \"In vitro methyltransferase assay, SMYD2 knockdown, K→A mutagenesis, pALK/pAKT Western blot and growth assays\",\n      \"pmids\": [\"28370702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Methylation site falls in the ALK rather than EML4 moiety\", \"Single-lab, in vitro plus cell-based only\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established native EML4 as a tubulin-tail-binding microtubule-associated protein regulated by mitotic NEK6/NEK7 phosphorylation at Ser144/Ser146, defining its physiological function in mitotic microtubule dynamics.\",\n      \"evidence\": \"Cryo-EM reconstruction, microtubule sedimentation, in vitro NEK6/NEK7 kinase assays, S144A/S146A mutagenesis, RNAi, live-cell chromosome congression imaging\",\n      \"pmids\": [\"31409757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How this regulation is co-opted in the fusion context not directly tested\", \"Other kinase inputs not excluded\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed that variant 3 EML4-ALK recruits NEK9/NEK7 to microtubules to stabilize them and drive migration independently of ALK kinase activity, revealing an ALK-independent EML4-driven mechanism of aggressiveness.\",\n      \"evidence\": \"EML4-ALK V3 cell models, immunofluorescence, migration assays, NEK9/NEK7 activation and microtubule-depolymerization rescue\",\n      \"pmids\": [\"32184261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway is targetable clinically untested here\", \"Generalizability to other variants unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that EML4-ALK forms phase-separated cytoplasmic condensates that concentrate MAPK/PLCγ/PI3K components and require an active ALK conformation, with aromatic EML4 residues driving phase separation, STAT3 signalling, and tumourigenesis.\",\n      \"evidence\": \"Phase-separation imaging in cells/GEMMs/organoids, aromatic-residue and salt-bridge mutagenesis, inhibitor-induced foci dissolution, STAT3 and tumour assays\",\n      \"pmids\": [\"33976114\", \"34661367\", \"34090412\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative link between condensate material state and signalling output incompletely defined\", \"Variant-specific condensate differences only partly mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected condensate biology to therapy resistance: condensates sequester GRB2/SOS1 to suppress basal RTK signalling, and ALK inhibition releases adapters and pulsatile paracrine ERK reactivation, while phase-separation-driven JAK-STAT signalling promotes adeno-to-squamous lineage transition.\",\n      \"evidence\": \"Optogenetic condensate manipulation, GRB2/SOS1 sequestration and ERK reporter assays, paracrine blockade; GEMMs, organoids, scRNA-seq and JAK-STAT inhibition for lineage transition\",\n      \"pmids\": [\"39488530\", \"38284990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term clinical efficacy of paracrine/JAK-STAT combination strategies not established\", \"Determinants of squamous-transition cell-of-origin specificity incompletely defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how native full-length EML4 microtubule and NEK regulation mechanistically intersect with fusion condensate formation to determine variant-specific signalling and durable resistance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking microtubule localization, condensate state, and downstream pathway selection\", \"Physiological (non-fusion) EML4 functions beyond mitosis uncharacterized in this corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [9, 12]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [9, 12, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 14, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 16, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ALK\", \"NEK7\", \"NEK6\", \"NEK9\", \"GRB2\", \"SOS1\", \"RAS\", \"SMYD2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":5,"faith_pct":100.0}}